Bazzi, Angela R.
Bordeu, Michelle
Baumgartner, Katrina
Sproesser, Darien M.
Bositis, Christopher M.
Krakower, Douglas S.
Mimiaga, Matthew J.
Biello, Katie B.
Funding for this research was provided by:
National Institute on Drug Abuse (R01DA051849, R01DA051849, R01DA051849, R01DA051849, R01DA051849, R01DA051849, R01DA051849)
National Institute of Allergy and Infectious Diseases (P30AI042853)
Article History
Received: 15 February 2023
Accepted: 11 March 2023
First Online: 17 March 2023
Declarations
:
: The study protocol was approved by the Fenway Health Institutional Review Board. Participants provide written informed consent. All research has and will be performed in accordance with relevant guidelines/regulations, including the Declaration of Helsinki.
: Not applicable.
: Dr. Biello reports receiving unrestricted research funds from Merck outside of the submitted work. Dr. Krakower has conducted research funded by grants from Merck and Gilead Sciences to Fenway Health, has received funds from Virology Education and UpToDate, Inc. to develop medical education content, and has received funds as a Consultant to Loma Linda University, University of Alabama Birmingham, and University of North Texas Health Sciences Center. The other authors have no conflicts of interest to declare.